Figure 2 | Scientific Reports

Figure 2

From: Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor

Figure 2

Treatment with an hIL6R-neutralizing antibody in humanized Castleman's disease model mice.

(a) Protocol for 4-week treatment with the anti-mouse Il6ra antibody, MR16-1, or the anti-human IL6R antibody, tocilizumab (TCZ). (iv.), intravenous injection; (sc.) subcutaneous injection. (b) Spleen weights of Il6ra+/+-hIL6 transgenic mice and (c) Il6rahIL6R/hIL6R-hIL6 transgenic mice after 4-week treatment (n = 5 per group). Statistical significances were determined by nonparametric comparisons with control using the Dunn method for joint ranking. The data of each treatment group were compared with those of the respective hIL6 non-transgenic mouse group in each genotype of interleukin-6 receptor, Il6ra+/+ (b) and Il6rahIL6R/hIL6R (c). *, p < 0.05, **, p < 0.01 and NS, not significant. Non Tg, hIL6 non-transgenic mice; Tg, hIL6 transgenic mice.

Back to article page